Comparing SG&A Expenses: Genmab A/S vs Summit Therapeutics Inc. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between Genmab A/S and Summit Therapeutics Inc. over the past decade.

Genmab A/S: A Steady Climb

From 2014 to 2023, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%. This reflects the company's aggressive expansion and investment in its operational infrastructure. By 2023, Genmab's SG&A expenses reached a peak, highlighting its commitment to scaling its operations.

Summit Therapeutics Inc.: A More Modest Growth

In contrast, Summit Therapeutics Inc. experienced a more modest increase of approximately 315% in the same period. This suggests a more conservative approach to managing operational costs, possibly focusing on strategic investments.

This comparison underscores the diverse strategies employed by biotech firms in managing their growth and operational expenses.